R&D Progress
Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma remains one of the most prevalent cancers worldwide, with approximately 510,000 new cases diagnosed annually (2018 data).
Diffuse Large B-cell Lymphoma (DLBCL) accounts for the largest share of non-Hodgkin lymphoma cases (approximately 30%) and follows a relatively aggressive disease course. Since the introduction of Rituximab, treatment outcomes for DLBCL have improved considerably; however, its high relapse rate continues to pose a challenge for many patients. LIB-101 is currently being evaluated in combination with Rituximab in a clinical trial enrolling DLBCL patients, with the goal of offering new treatment options.
Cutaneous T-Cell Lymphoma (CTCL) is a rare CD4+ T-cell lymphoma of the skin, with a prevalence of approximately 11.32 cases per million people. The disease course is typically long and indolent, and most patients live with the condition for decades following diagnosis. Repeated treatments and the significant decline in quality of life caused by the disease place a considerable burden on both patients and the healthcare/insurance system. Clinical trial results show that LIB-101 combined with total skin electron beam therapy (TSEBT) extends patients' duration of response and reduces many of the side effects associated with treatment.
Diffuse Large B-cell Lymphoma (DLBCL) accounts for the largest share of non-Hodgkin lymphoma cases (approximately 30%) and follows a relatively aggressive disease course. Since the introduction of Rituximab, treatment outcomes for DLBCL have improved considerably; however, its high relapse rate continues to pose a challenge for many patients. LIB-101 is currently being evaluated in combination with Rituximab in a clinical trial enrolling DLBCL patients, with the goal of offering new treatment options.
Cutaneous T-Cell Lymphoma (CTCL) is a rare CD4+ T-cell lymphoma of the skin, with a prevalence of approximately 11.32 cases per million people. The disease course is typically long and indolent, and most patients live with the condition for decades following diagnosis. Repeated treatments and the significant decline in quality of life caused by the disease place a considerable burden on both patients and the healthcare/insurance system. Clinical trial results show that LIB-101 combined with total skin electron beam therapy (TSEBT) extends patients' duration of response and reduces many of the side effects associated with treatment.
Medical Countermeasures
Medical countermeasures refer to the emergency medical needs and supply required in the event of chemical, biological, radiological, or nuclear (CBRN) disaster exposure. Such emergencies are typically unpredictable and result in large-scale casualties, making it essential to establish medical demand planning and a stable, stockpiled supply chain to respond to unexpected disasters. In experimental studies against radiological and nuclear disaster scenarios, LIB-101 has demonstrated favorable safety and efficacy—following exposure to high-dose radiation, a single dose of LIB-101 was able to effectively improve survival in irradiated subjects.
Immuno Checkpoint Blockade Combination Therapy
Immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 therapies, have increasingly become a new option in cancer treatment, with the market growing at approximately 18% annually; according to 2021 data, global sales reached approximately US$18 billion. However, in clinical practice, only a small subset of cancer patients achieve a significant treatment response with checkpoint inhibitors. Preclinical studies and mechanistic data suggest that LIB-101 can effectively increase the overall proportion of responders. We plan to expand this combination therapy across different cancer types in clinical trials, with the goal of benefiting a much larger patient population.
© Copyright | LIBO PHARMA CORP. | All rights reserved | Private Policy 2024